Article:Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. (5579594)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q41583750. Its title is Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. and the publication date was 2017-07-26. The initial author is Tannaz Eslamparast.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Nutrients

Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease

  • Tannaz Eslamparast
  • Puneeta Tandon
  • Maitreyi Raman

1Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2X8, Canada; eslampar@ualberta.ca (T.E.); ptandon@ualberta.ca (P.T.)

2Cirrhosis Care Clinic and CEGIIR, University of Alberta, Edmonton, AB T6G 2X8, Canada

3Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, AB T6G 2X8, Canada

Publication date (epub): 7/2017

Publication date (collection): 8/2017

Abstract

Poor dietary composition is an important factor in the progression of non-alcoholic fatty liver disease (NAFLD). The majority of NAFLD patients follow diets with overconsumption of simple carbohydrates, total and saturated fat, with reduced intake of dietary fiber and omega-3 rich foods. Although lifestyle modifications including weight loss and exercise remain the keystone of NAFLD management, modifying dietary composition with or without a calorie-restricted diet may also be a feasible and sustainable strategy for NAFLD treatment. In the present review article, we highlight the potential therapeutic role of a “high quality healthy diet” to improve hepatic steatosis and metabolic dysfunction in patients with NAFLD, independent of caloric restriction and weight loss. We provide a literature review evaluating the evidence behind dietary components including fiber-, meat- and omega-3-rich diets and, pending further evidence, we concur with the EASL-EASD-EASO Clinical Guidelines recommendation of the Mediterranean diet as the diet of choice in these patients.

Paper

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is one of the most common non-communicable diseases worldwide, affecting 25–30% of the global population, with the highest prevalence in the Middle East and South America. In North America and Europe, one-fourth of the adult population has NAFLD [[1],[2]]. The major established risk factors for NAFLD include obesity, insulin resistance and dyslipidemia [[3]]. The NAFLD spectrum ranges from simple liver steatosis to hepatic necroinflammation called non-alcoholic steatohepatitis (NASH) with or without fibrosis. This may progress to advanced cirrhosis and hepatocellular carcinoma (HCC) [[4],[5]]. NAFLD acts in synergy with related metabolic risk factors and other existing conditions to promote the development of HCC [[6]], and importantly, HCC can be seen in the absence of cirrhosis in this condition [[7]]. The burden of NAFLD continues to increase. It is the third leading cause of liver transplantation and, by 2030, it is predicted to become the most common reason for transplantation in the United States [[8]].

The majority of NAFLD patients overconsume fructose, red meat and saturated fat [[9],[10]]. In addition they have reduced intake of dietary fiber and omega-3 rich food [[9],[10]]. This pattern of dietary intake can lead to obesity and the metabolic syndrome, increasing the risk for NAFLD. In addition, there is emerging evidence that a deleterious dietary composition may predispose people to NAFLD, even in the absence of obesity [[11],[12]].

Lifestyle modifications involving weight loss and exercise remain the cornerstone of NAFLD management [[13]]. Caloric restriction is the most important element in nutrition intervention for NAFLD patients and plays a critical role in visceral, subcutaneous and hepatic fat reduction, and weight loss [[14]]. Weight reduction of 3–5% can cause a notable decrease in hepatic fat and improvement in insulin sensitivity [[15]]. However, weight loss and weight maintenance remain a considerable challenge for many individuals. Conceivably, modifying dietary composition with or without a calorie-restricted diet may be a feasible and sustainable strategy for NAFLD management. As such, the present review focuses on addressing the potential role for modifying dietary composition and dietary patterns in the management of NAFLD—interventions that may have efficacy with or without weight loss.

2. Definition of NAFLD

NAFLD is a hepatic manifestation of the metabolic syndrome [[16]]. It encompasses a broad pathological spectrum of disease characterized by excessive hepatic triacylglycerol (TAG) deposits in more than 5% of hepatocytes in patients with little or no history of alcohol consumption [[4],[13]].

3. Pathophysiology of NAFLD

The pathophysiology of NAFLD is complex and includes numerous genetic, dietary, metabolic and hormonal factors. In 1998, Day and James proposed the “2-hit hypothesis” [[17]] to explain the progression from steatosis to NASH. New insights suggest a multiple hit hypothesis, with the first hit of insulin resistance leading to increased fat accumulation within the hepatocyte. The steatotic liver is vulnerable to lipid peroxidation, impaired hepatocyte apoptosis and increased cytokine activity [[17]]. In addition, a complex interplay between multiple factors such as oxidative stress-mediated lipotoxicity, proinflammatory adipokines and mitochondrial dysfunction act in parallel with genetic predisposition to advance disease. Dietary carbohydrate (CHO) intake and insulin resistance may inhibit the reduction of reactive oxygen species and represent potential additional hits in a susceptible individual [[18]]. This multiple hit theory provides a broader pathophysiologic view of NAFLD compared to the “two-hit” theory [[19],[20]].

3.1. Lipid Metabolism

Obesity and insulin resistance can result in an elevated free fatty acid (FFA) flux induced by dysregulation of de novo lipogenesis (DNL), lipolysis of visceral fat, and dietary fat. Increased hepatic FFA flux leads to excess fat deposition in hepatocytes with a large metabolic load and promote hepatocyte lipotoxicity and oxidative stress [[21]]. Ultimately, the additive effects of cytokines released by Kupffer cells and activation of the immune response and cell death pathways meditate the transition to NASH [[22],[23]].

3.2. Glucose Metabolism

CHO intake can also stimulate hepatic lipogenesis by converting excess glucose to fatty acids. Under normal conditions, insulin transports glucose into the cell to be stored as glycogen [[24]]. Hepatic steatosis occurs when impaired insulin signaling results in compensatory hyperinsulinemia. In this situation, glucose absorption decreases in skeletal muscle providing further substrate for DNL. Hyperinsulinemia also decreases glycogen synthesis, increases hepatic FFAs uptake, alters TAG transportation, and inhibits β-oxidation [[22],[25]].

3.3. Gut Microbiome

The gut microbiota has been implicated in obesity, diabetes, metabolic syndrome and NAFLD through effects on calorie salvage, host energy metabolism, proinflammatory signaling, and via direct hepatotoxicity of bacterial products [[26]]. Obese humans may have a fundamentally different gut microbiota, with decreased diversity, but increase in the representation of the phylum Firmutes and proportionate decrease in Bacteroidetes compared with lean individuals [[27]]. Microbes produce several hundred volatile organic compounds, including ethanol, of which the systemic effects are unknown [[28]]. Our group has previously shown that in obese patients with clinically suspected NAFLD, a significantly altered fecal volatile organic compound profile and compositional shift in the fecal microbiome is observed [[29]]. In this study, we were unable to replicate previous observations of phylum-level differences in the fecal microbiota. Additional study findings revealed that ester volatile organic compounds were identified more frequently in NAFLD compared to controls. Conceivable the volatile organic compounds are of bacterial origin, however, the role of diet in the genesis of volatile organic compounds cannot be excluded [[30]]. The gut-liver axis has a pivotal role in the development and progression of NAFLD [[31]]. Gut-derived lipopolysaccharides (LPS), a component of gram-negative bacteria induces liver injury by invoking a cascade of morphological, biochemical and functional changes such as insulin resistance, increased hepatic oxidative stress, acute inflammatory responses, metabolic deregulation and fibrosis [[32],[33]]. Bacterial translocation is a process in which alterations in tight junction proteins reduce the intestinal barrier integrity, resulting in increased endotoxin absorption. In a healthy individual, these bacterial products are rapidly cleared by the hepatic immune system, but in an injured liver, they can result in the release of reactive oxygen metabolites, proteases and other degenerative enzymes, which worsen liver damage [[34],[35]]. Over the last decade, increased gut permeability and elevated levels of LPS in the serum have been documented in NAFLD and NASH patients [[36]]. Gut dysbiosis therefore plays a role in the development and progression of liver damage and in the severity of NAFLD, NASH and their complications [[37]].

3.4. Visceral Adipose Tissue vs. Subcutaneous Adipose Tissue (VAT: SAT)

Adipose tissue is a complex, active endocrine organ. It contributes to the pathogenesis of NAFLD by modulating insulin sensitivity by secreting adipocytokines. Visceral fat tissue (VAT) is densely infiltrated with macrophages, promotes inflammation, stimulates proinflammatory cytokine secretion such as TNF-α, and Interlukin-6 (IL-6), and inhibits insulin sensitivity of adipocytes [[22]]. Expression of TNF-α is greater in VAT compared to subcutaneous fat (SAT), and can trigger proinflammatory pathways [[38]], which disrupt insulin signaling and increase steatosis. Conversely, adiponectin, a protein hormone with anti-inflammatory properties, produced by adipocytes, has decreased secretion in VAT, leading to altered lipid metabolism and increased inflammation [[22]].

4. Observations of Dietary Composition and Patterns in NAFLD

4.1. Calorie, Macronutrient Composition and Dietary Fiber

The relationship between diet and the development of NAFLD is complex and extends beyond total energy intake. Assessment of total energy intake in patients with NAFLD compared with controls demonstrates discordant results. Although some investigators have shown higher energy intake in NAFLD compared to healthy controls [[39]], others have identified similar energy intake in both groups, with notable differences in dietary composition [[40]]. Cortez-Pinto and colleagues identified significantly lower protein and CHO, and higher total fat and n-6 consumption in NAFLD patients compared to controls [[40]]. Musso et al. showed that patients with NASH compared to controls had non-significantly higher intake of total fat; in contrast, higher intake of saturated fat, and lower PUFA consumption was observed in NASH compared to controls [[11]]. Recently, Wehmeyer and colleagues found no differences in the consumption of fat between NAFLD patients and controls [[39]]. The divergent study results may arise due to heterogeneous patient populations (NAFLD vs. NASH) and/or varying dietary data capture tools.

Several studies have focused on the detrimental effects of high consumption of simple CHO on hepatic and metabolic functions in NAFLD [[9],[15]]. Recently, a study observed a significantly higher glucose intake per 1000 kcal in patients with NAFLD compared to controls [[39]]. In 2007, a group of investigators reported that simple CHO consumption, particularly from soft drinks, in subjects diagnosed with NAFLD was significantly greater than in subjects with a normal liver (23 ± 42 vs. 12 ± 24 g/day, p-value = 0.03). The result was sustained even after adjusting for sex, age, BMI and total calorie intake (OR = 1.45, 95% CI 1.13–1.58) [[10]]. Volynets identified a higher intake of protein, total carbohydrates, monosaccharides and disaccharides compared with controls [[41]]. A study of 28 patients with NASH and 18 patients with simple steatosis supported that a diet rich in CHO, particularly sweets and not cereals, was associated with higher risk of NASH compared to simple steatosis [[42]]. Although, this study found a significant association in both sexes, another study in 2015 reported that a high-CHO/sweet dietary pattern, characterized by high intakes of fruit, cakes, soft drinks and sugary snacks, was positively associated with risk of NAFLD only in females. They also showed that females in the highest quartile had a greater risk of developing NAFLD than those in lowest quartile, after adjustment for cofounding factors (OR = 2.19, 95% CI 1.4–3.46), while no association was observed in males [[43]]. These findings are consistent with the observation in the study by Tajitma et al. [[44]], who investigated the relationship between CHO intake and NAFLD prevalence in middle-aged Japanese.

Regarding the protein content of the diet, several studies have reported a significantly higher protein intake in patients with NAFLD compared to controls [[10],[39],[40],[41]], while other studies found no difference [[11],[45]]. In 2016, Kobayashi, et al. [[46]] compared the dietary intake of Japanese patients with NAFLD and T2D. Their results showed a significantly higher energy ratio from protein in NAFLD patients than in T2D (p = 0.008).

Poor fiber intake is common in NAFLD [[39],[40]]. In a series of 25 NASH patients and 25 matched healthy controls, the mean daily fiber intake was almost 50% lower in NASH versus control patients (13 ± 4 g vs. 23 ± 8 g, p = 0.0001) [[11]]. This is supported by a subsequent study showing lower fiber intake in NAFLD patients as compared to controls [[39]]. In a study from Japan, patients with NAFLD had a lower vegetable intake and a higher consumption of fruits and sweets compared to T2D patients [[46]]. In 2016, Cheng and colleagues [[45]] assessed the relationship between dietary intake and hepatic lipid content in NAFLD, and showed that fiber intake was inversely associated with hepatic fat fraction and intrahepatic lipid.

Taken together, the macronutrient composition of the diet, particularly high independent consumption of CHO, simple sugars, fat and protein, and low fiber intake may be associated with the risk of NAFLD, independent of energy overconsumption. The mechanism by which the intake of certain nutrients may influence the disease has not yet been completely understood.

4.2. Meat (Red Meat vs. Other)

High meat intake is associated with glucose intolerance, impaired insulin sensitivity, and may increase the risk of T2D [[37],[47]]. Although T2D is accepted as a risk factor for NAFLD, there are no data investigating the direct association between intake of dietary protein sources and NAFLD. A recent cross-sectional study [[10]] showed that subjects with NAFLD consumed 27% more protein from all types of high and low fat meat (beef, liver, sausage, lamb, chicken and turkey) compared to subjects without NAFLD. Even after adjusting for sex-, age-, BMI- and total calorie intake-, a higher protein intake resulted in a higher risk of NAFLD. Interestingly, when the type of protein intake was considered, the intake of protein from fish high in omega-3 trended to decrease the risk of NAFLD (OR = 0.73, 95% CI 0.52–1.04). Although, this study found no significant difference in the consumption of different types of meat and fats, another case-control study reported that the intake of red meat was significantly higher in NAFLD cases compared to controls [[48]]. Notably, in the latter study, the meat consumption in both study groups exceeded the recommendation level of Chinese Dietary Pagoda (75 g/day). Findings showed no significant differences in white meat consumption between NAFLD and control groups [[48]].

High intake of processed meat has also been associated with an increased risk of NAFLD. This may be linked to the high content of sodium, saturated and trans-fatty acids in these products [[49],[50]].

There are several possible explanations for the potential role of red meat intake in NAFLD: (a) red meat is high in saturated fat and cholesterol; (b) presence of preservatives and additives in processed meat; (c) presence of other dietary factors with negative effects in individual with high meat intake, since they usually follow a “Western” dietary pattern, which has been linked to hypertension, diabetes, obesity and certain cancers [[47],[51],[52]].

4.3. Omega-3 Rich Diets

Dietary sources of omega-3 PUFAs, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are found in with highest concentration in seafood, mostly fatty fishes including pilchards, sardines, mackerel, trout, salmon, herring and tuna. Marine omega-3 PUFAs are also found in lean fish (haddock, cod, and crustaceans), shellfish, and fish oils with lower concentrations [[53]]. Omega-3 PUFAs are also found in certain vegetable oils such as flaxseed oil. Studies have associated a higher consumption of fish rich in omega-3 with a reduced risk of NAFLD [[10]]. This has been supported by case-control studies reporting a significantly lower concentration of omega-3 PUFA, especially DHA, in NAFLD patients than in healthy individuals [[54],[55],[56]]. There are few data concerning hepatic fatty acid composition in patients with NAFLD. In one study, NAFLD patients had a depletion of omega-3 PUFAs in hepatic TAG. The low level of circulating omega-3 PUFAs was associated with greater rates of lipogenesis and hepatic FFA flux along with a reduction in VLDL synthesis and β-oxidation, promoters of NAFLD to its necroinflammatory form, NASH [[54]]. Similarly, a study by Allard et al. [[30]] compared three groups of patients (NASH, elevated liver enzymes with minimal histological findings and patients with simple steatosis). They showed that NASH patients had a total PUFA intake below the recommended level and lower hepatic omega-3 and omega-6 compared to the other two groups. There were no differences in n-6/n-3 ratio among the three study groups [[30]].

5. Dietary Intervention on NAFLD Outcomes

Lifestyle modification is the first-line treatment option, with weight loss via a hypocaloric diet being the most important therapeutic target in NAFLD [[57]]. There is evidence in support of particular diets, most notably the Mediterranean diet (Table A1) [[58]].

5.1. Mediterranean Diet

A “Mediterranean diet” (MD) is a dietary pattern originally inspired by the traditional diet in Mediterranean countries, characterized by a high consumption of plant-based foods, such as vegetables, fruits, whole grains, seeds, nuts and legumes, and moderate consumption of protein-source foods such as fish and poultry (Table 1). This diet is rich in monounsaturated fatty acids (MUFA) primarily from olive oil and olives, reduced fat dairy products and low red meat intake. It has proven beneficial effects on the prevention of cardiovascular disease, hypertension, hypercholesterolemia, and obesity [[59],[60]]. In 2014, a small observational study explored the potential association between a Mediterranean diet and the presence and the severity of NAFLD. Kontogianni et al. [[61]] found that a greater adherence to the Mediterranean diet was significantly correlated with a lower degree of hepatic steatosis and insulin resistance in patients with biopsy-proven NASH compared to simple fatty liver. The MD score was negatively correlated with the serum alanine aminotransferase (ALT), insulin resistance index, and the severity of steatosis [[61]].

The Mediterranean diet has been shown to reduce hepatic fat and improve hepatic insulin sensitivity even without weight loss in NAFLD patients [[62]]. Adherence to Mediterranean diet has also been linked to less advanced NAFLD and a lower risk of having the metabolic syndrome in this patient population [[58]]. Two randomized trials have contributed the most to the evidence for a potential beneficial effect for the MD in NAFLD. In a randomized parallel-group design, 37 men and 8 women with T2D were assigned to a 28-week isocaloric diet (high CHO/high fiber or high MUFA). There was a greater decrease in hepatic steatosis in the MUFA compared to the high CHO diet (29% vs. 4%) [[63]]. Additionally, another randomized cross-over trial assessed the impact of a MD compared to a standard low-fat high-CHO in non-diabetic NAFLD patients. A significant reduction in hepatic steatosis was observed with the MD [[64]]. Accordingly, the MD has been recommended as the diet of choice for the treatment of NAFLD by the EASL-EASD-EASO Clinical Practice Guidelines [[13],[65]]. There are multiple potential mechanisms for the observed benefits of the MD on the course of NAFLD. Extra-virgin olive oil (EVOO) is a frequently identified dietary component of the MD, containing over 30 phenolic compounds. Phenolic compounds are known to exhibit antioxidant properties [[66]]. In addition, EVOO has been shown to reduce postprandial blood glucose levels and LDL potentially mediated through glucagon like peptide 1 upregulation [[65]]. Through various mechanisms, n-3 fatty acids in fish oil have been shown to reduce hepatic lipid accumulation, improve insulin sensitivity and have anti-inflammatory effects [[65]]. Higher intake of fruits and vegetables can reduce the energy density of the diet contributing to an important role in weigh management. Moreover, polyphenols and carotenoids contained in fruits and vegetables display beneficial effects on metabolic homeostasis and exert anti-inflammatory and anti-fibrotic effects, in NAFLD models, while suppressing activation of hepatic stellate cells [[67]]. High-fiber diets and whole grains have the potential to beneficially influence gut microbiota composition, which can be of relevance to the gut liver axis in the progression of NAFLD [[68]].

It should also be noted that a Mediterranean diet may be associated with a Mediterranean lifestyle, which may include adequate rest periods, differences in sun exposure and optimal physical activity, all of which may have a positive but independent impact on the course of NAFLD. Future well-designed studies exploring the longer term impact of the MD on the spectrum of NAFLD are required.

5.2. DASH Diet

A “Dietary Approach to Stop Hypertension” (DASH) diet is a dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, fish, poultry, nuts and legumes but with emphasis on low intake of sodium, total fat, saturated fat, cholesterol and added sugars (Table 1). The DASH diet is high in fiber, potassium, calcium and magnesium [[69]]. Although this dietary pattern was primarily designed for lowering blood pressure [[69]], by directly playing a beneficial role in insulin resistance and dyslipidemia [[70]] it has recently shown beneficial effects on other metabolic disorders including T2D [[71]], cardiovascular disease [[72]], and NAFLD [[73],[74]]. A recent case-control study in 102 patients with newly diagnosed NAFLD and 204 matched controls evaluated the association between adherence to the DASH diet and the risk of NAFLD using a validated food frequency questionnaire. Although there was an inverse association between the DASH-style diet and risk of NAFLD, after adjusting for BMI and dyslipidemia the significance of this relationship disappeared [[73]]. In a recent eight-week RCT conducted in overweight and obese patients with NAFLD, the DASH diet resulted in a significant reduction in body weight, serum TG level, VLDL-cholesterol and liver enzymes, and concurrent improvement in insulin sensitivity, biomarkers of oxidative stress and inflammation (high sensitivity-CRP, nitric oxide (NO), glutathione (GSH) malondialdehyde) in the intervention group compared to controls [[74]].

Possible mechanisms for the protective role of the DASH diet include: (i) High fruit and vegetable consumption, resulting in higher intake of antioxidants [[75]], which may suppress the inflammatory processes in NAFLD; (ii) Higher intake of whole grains, which are associated with a lower risk of comorbidities linked to NAFLD [[76]]; (iii) Increased intake of nuts, which are rich in MUFAs, PUFAs and vitamin E, which may improve the serum lipid profile, reduce blood pressure, and have a favorable impact on oxidative stress [[77]]; (iv) Lower dietary intake of simple sugar. High sugar intake is associated with dyslipidemia, insulin resistance and central obesity [[78]]; (v) Higher intake of calcium and magnesium content of the DASH diet may have beneficial effects on insulin sensitivity and the anti-inflammatory response by decreasing oxidative activity and restoring anti-oxidative enzymes [[79],[80],[81]]. More studies are required in this field to determine the features of the DASH diet that are associated with the most benefit in patients with NAFLD.

5.3. Fiber Intervention (Soluble, Prebiotic)

Prebiotics are known as selectively fermented ingredients modulating changes in the composition and activities of the gut microbiome [[82]]. Prebiotics are often considered to be a subset of dietary fiber; however, not all dietary fiber has prebiotic qualities [[36]]. Prebiotic fiber is naturally found in foods such as garlic, asparagus, leek, chicory root and onions [[26]]. Benefits of prebiotics include: (i) stimulating bacterial production of short chain fatty acids; (ii) a selective modification of gut microbiota composition, reduction of the luminal pH, inhibition of pathogen growth; (iii) improvement in glucose and lipid metabolisms [[26]]. We lack well-designed studies to evaluate the effects of prebiotic fiber on NAFLD. A review article reported that in patients with T2D and hyperlipidemia who consumed either inulin or fructooligosaccharide (FOS) supplements (prebiotic fiber), improvements in the TG (6–20% reduction), cholesterol (14–27% reduction) levels, or both were noted [[83]]. Oligofructose supplementation for three months significantly reduced body weight in overweight and obese adults, decreased self-reported calorie intake and improved glycemia [[84]]. Only one pilot study has assessed the effect of prebiotic fiber in NAFLD. In this study, seven NASH patients received 16 g/day of oligofructose in a randomized, double-blinded, crossover study. The results showed a significant decrease in serum ALT and aspartate aminotransferase (AST) levels, and an improvement in insulin level after four weeks [[85]].

5.4. Omega-3 Interventions

Several clinical studies have evaluated the impact of algal or marine omega-3 PUFAs on hepatic endpoints in NAFLD [[47]]. A recent study documented that marine omega-3 PUFA modulate hepatic lipid composition and TAG metabolism, and elevate mediators with anti-inflammatory features. All these modulations are beneficial in NAFLD treatment [[86],[87]]. One of the first studies investigating the impact of omega-3 PUFA dates back to 2006 [[88]]. In this study, Cappani et al. demonstrated that fish oil (1 g/day for 12 months) as compared to control, resulted in a 60% improvement in risk factors such as a significantly decreasing the serum AST), ALT, γ-glutamyl transpeptidase (GGT), improving liver steatosis and reducing the n-6/n-3 ratio (p = 0.0001) [[88]]. Since that time, a series of clinical trials and pilot studies have also supported the beneficial effects of omega-3 PUFAs with results on liver enzymes and hepatic steatosis. In 2008, two studies investigated the effect of calorie restricted diets with and without fish oil consumption [[89],[90]]. Findings showed that fish oil in addition to calorie restriction was more protective than calorie restriction alone for the treatment of NAFLD. In another study, omega-3 PUFAs (2.7 g/day for 12 months) reduced plasma TAG level by 4.3% compared with baseline data, but had no effect on hepatic steatosis, inflammation, ballooning, or fibrosis score, and showed no improvement in liver enzymes levels, insulin resistance or proinflammatory markers [[91]]. Recently, two RCTs [[92],[93]] used flaxseed oil as a source of omega-3 PUFAs in patients with NAFLD. One study showed a significantly greater reduction in liver enzymes, hepatic steatosis and fibrosis scores in flaxseed plus lifestyle modification compared to lifestyle modification alone [[93]]. In another study, Noguiera et al. used a mix of flaxseed oil and fish oil (0.945 g n-3/day) and compared the results with mineral oil (2 mL/day). No histological improvement was found after a six-month intervention, except an improvement in lobular inflammation in the group receiving mineral oil [[92]]. Among all published reports using omega-3 PUFAs for NAFLD treatment, only five studies suggested that omega-3 PUFAs improved NAFLD independent of weight loss. Taken together, the data are discordant and larger well-designed clinical trials for longer periods are still needed to fully evaluate the beneficial effects of omega-3 PUFAs in NAFLD.

5.5. Low-Fat vs. Low-CHO Interventions

Low-CHO diets have become a common strategy for weight management across a variety of conditions. Although, a few studies have demonstrated that low CHO diets provide initial benefits on insulin resistance and liver fat, these results have not been sustainable in the long-term [[94],[95]]. In 2011, Haufe et al. [[96]] performed a six-month trial comparing the effects of reduced fat and reduced CHO hypocaloric diets on intrahepatic fat assessed by magnetic resonance tomography in overweight and obese individuals. The results showed that a prolonged intervention with either low-CHO or low-fat diets had same effect on intrahepatic lipid accumulation, independent of visceral fat loss and changes in insulin sensitivity [[96]]. Another three-month intervention study was conducted in obese subjects with two intervention groups—one group received a calorie-restricted diet (1100 kcal/day) with low-CHO content (<50 g/day) and the second group followed an isocaloric high-CHO diet (>180 g/day). The result after 48 h showed an almost 30% reduction in intrahepatic TG in patients on the low-CHO diet and only a 10% decrease on the high-CHO diet. The decrease of intrahepatic TG at the end of the study was similar in the two groups (40–50% reduction) [[95]]. In five biopsy-proven NAFLD patients, a six-month low-CHO ketogenic diet (CHO less than 20 g per day) resulted in a significant improvement in steatosis and inflammatory response (p = 0.02) with a trend toward improvement in fibrosis [[97]]. Although interesting, these results are inconclusive given the absence of a comparative arm and the possibility that improvement may have been due to weight loss alone and not the particular diet. In another study, De Luis et al. [[98]] explored the effects of either a low-CHO or low-fat hypocaloric diet in NAFLD and obese patients for three months. In the NAFLD group, the low-fat diet showed weight loss had an improvement in anthropometric measurements (BMI, weight, fat mass), cardiovascular risk factors (blood pressure, TG, LDL- and total cholesterol levels) and liver enzymes (ALT, AST, GGT). The low-CHO diet resulted in an improvement in same parameters without statistical changes in AST [[98]]. A recent meta-analysis study supports that both low/moderate fat (≤30% of daily calorie intake) and moderate CHO (≤45% of daily calorie intake) diets have a similar beneficial effect on liver function by reducing ALT and AST levels [[99]].

Thus far, the limited available evidence supports the absence of a difference between low-CHO and low-fat diets as long as they are both calorie-restricted diets [[96]]. Long-term, interventional studies comparing these two diets, low-CHO and low-fat diets, are needed with an assessment of hepatic outcomes in patients with NAFLD.

5.6. Probiotics

Altered gut microbiota is associated with obesity, a risk factor for NAFLD. In animal studies, probiotics have been shown to prevent liver fibrosis [[100]]. In humans, Wong et al. demonstrated that patients with biopsy proven NASH treated with probiotics (Lactobacilli strains plus Bifidobacterium bifidum) compared with usual care had significantly lower intrahepatic triglyceride content measured by proton-magnetic resonance spectroscopy, independent of effect on BMI, waist circumference glucose or lipid levels [[101]]. Aller and colleagues investigated the impact of probiotic supplementation in 28 adults with NAFLD over three months. The probiotic intervention was comprised of 500 million colonies of Lactobacillus bulgaricus and Streptococcus thermophiles. Therapy was associated with a significant reduction in liver enzymes (ALT, AST and GGT; p < 0.05) compared to the placebo group. No significant changes were found in anthropometrics and cardiovascular risk factors between groups [[102]]. Only one study evaluated an intervention using a probiotic food in NAFLD [[103]]. This randomized, double-blind, placebo-controlled clinical trial showed that consuming a probiotic yogurt with L. acidophilus La5 and B. lactis Bb12 for eight weeks in NAFLD patients reduced hepatic aminotransferases, and total and LDL cholesterol compared to patients consuming conventional yogurt [[103]]. In summary, the limited available data support the benefit of some probiotics, presumably related to modulation of liver function and reduction in dysbiosis, hepatic fat and TNF-α production. The translation of these findings to clinical practice is limited by the small number of studies and the variations in the probiotic strains, doses, and duration of the intervention period chosen across studies.

6. Our Recommendations

Weight loss achieved through lifestyle modification is the mainstay of therapy for NAFLD. Unfortunately, the sustainability of weight loss is poor and recidivism is frequently encountered, resulting in inadequate disease control. In this review we aimed to highlight the potential therapeutic role of a “high quality healthy diet” to improve liver steatosis and metabolic dysfunctions in patients with NAFLD above and beyond the known benefit of caloric restriction and weight loss. Our suggested dietary recommendations to manage NAFLD using dietary interventions include a eucaloric diet that is focused in the following principles: (a)

Moderate to high CHO intake: The recommended CHO intake is 45–65% of total daily calories, with a low preference for simple and unrefined sugar such as fructose-containing beverages and food; High preference for whole grains and low glycemic index foods. This improves hepatic fat accumulation and decreases hepatic fat accumulation.

(b)

Low to moderate fat intake: The recommended fat intake is below 30–35% of total calories with a low preference for saturated and trans fat intake; High preference for healthy fat intake (MUFA and omega-3 PUFAs) found for example in olives, olive oil, seeds, nuts and fatty fish. This promotes glycemic control and may reduce inflammatory responses.

(c)

Protein intake: The recommended protein intake is 15–20% of total daily calories, with minimization of red meat intake particularly processed meat, and increased consumption of poultry, fish, low- or non-fat dairy products and a blend of vegetable protein sources (beans and legumes). This improves cardiovascular risk factors and insulin sensitivity and decreases the risk of morbidity and mortality.

(d)

Fiber and antioxidant intake: Increased consumption of fruits and vegetables, with more focus on prebiotic fiber. This provides beneficial effects on hepatic metabolism, which may be mediated through gut microbiome changes and reduction in calorie intake.

(e)

Consider daily intake of probiotic enriched yogurt, containing L. acidophilus.

At this time, we do not have a definitive answer for the optimal proportions of total macronutrients (CHO, fat and protein) in the diet of NAFLD patients. A dietary composition based on the above recommendations may be of benefit in NAFLD, and overlaps with the Mediterranean Diet, which the EASL–EASD–EASO Clinical Guidelines have also recommended as the diet of choice for NAFLD treatment. Future studies evaluating the therapeutic effects of sustainable isocaloric dietary compositional changes will further increase our knowledge in this area.

References

  1. Y. FazelA.B. KoenigM. SayinerZ.D. GoodmanZ.M. YounossiEpidemiology and natural history of non-alcoholic fatty liver diseaseMetabolism2016651017102510.1016/j.metabol.2016.01.01226997539
  2. Z.M. YounossiA.B. KoenigD. AbdelatifY. FazelL. HenryM. WymerGlobal epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomesHepatology201664738410.1002/hep.2843126707365
  3. L. AbenavoliN. MilicL. Di RenzoT. PrevedenM. Medic-StojanoskaA. De LorenzoMetabolic aspects of adult patients with nonalcoholic fatty liver diseaseWorld J. Gastroenterol.2016227006701610.3748/wjg.v22.i31.700627610012
  4. P. AnguloNonalcoholic fatty liver diseaseN. Engl. J. Med.20023461221123110.1056/NEJMra01177511961152
  5. R. LoombaA.J. SanyalThe global NAFLD epidemicNat. Rev. Gastroenterol. Hepatol.20131068669010.1038/nrgastro.2013.17124042449
  6. S. YatsujiE. HashimotoM. TobariM. TaniaiK. TokushigeK. ShiratoriClinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis CJ. Gastroenterol. Hepatol.20092424825410.1111/j.1440-1746.2008.05640.x19032450
  7. G. GuzmanE.M. BruntL.M. PetrovicG. ChejfecT.J. LaydenS.J. CotlerDoes nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?Arch. Pathol. Lab. Med.20081321761176610.1043/1543-2165-132.11.176118976012
  8. J. VizueteA. CameroM. MalakoutiK. GarapatiJ. GutierrezPerspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future TherapiesJ. Clin. Transl. Hepatol.20175677510.14218/JCTH.2016.0006128507929
  9. X. OuyangP. CirilloY. SautinS. McCallJ.L. BruchetteA.M. DiehlR.J. JohnsonM.F. AbdelmalekFructose consumption as a risk factor for non-alcoholic fatty liver diseaseJ. Hepatol.20084899399910.1016/j.jhep.2008.02.01118395287
  10. S. Zelber-SagiD. Nitzan-KaluskiR. GoldsmithM. WebbL. BlendisZ. HalpernR. OrenLong term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based studyJ. Hepatol.20074771171710.1016/j.jhep.2007.06.02017850914
  11. G. MussoR. GambinoF. De MichieliM. CassaderM. RizzettoM. DurazzoE. FagaB. SilliG. PaganoDietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitisHepatology20033790991610.1053/jhep.2003.5013212668986
  12. K. YasutakeM. NakamutaY. ShimaA. OhyamaK. MasudaN. HarutaT. FujinoY. AoyagiK. FukuizumiT. YoshimotoNutritional investigation of non-obese patients with non-alcoholic fatty liver disease: The significance of dietary cholesterolScand. J. Gastroenterol.20094447147710.1080/0036552080258813319058085
  13. European Association for the Study of the Liver (EASL)European Association for the Study of Diabetes (EASD)European Association for the Study of Obesity (EASO)EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver diseaseJ. Hepatol.2016641388140210.1016/j.jhep.2015.11.00427062661
  14. L. FontanaT.E. MeyerS. KleinJ.O. HolloszyLong-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humansProc. Natl. Acad. Sci. USA.20041016659666310.1073/pnas.030829110115096581
  15. V. RatziuNon-pharmacological interventions in non-alcoholic fatty liver disease patientsLiver Int.201737Suppl. 1909610.1111/liv.1331128052636
  16. J.P. OngZ.M. YounossiEpidemiology and natural history of NAFLD and NASHClin. Liver Dis.20071111610.1016/j.cld.2007.02.00917544968
  17. C.P. DayPathogenesis of steatohepatitisBest Pract. Res. Clin. Gastroenterol.20021666367810.1053/bega.2002.033312406438
  18. A.P. RoloJ.S. TeodoroC.M. PalmeiraRole of oxidative stress in the pathogenesis of nonalcoholic steatohepatitisFree Radic. Biol. Med.201252596910.1016/j.freeradbiomed.2011.10.00322064361
  19. A. TakakiD. KawaiK. YamamotoMultiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)Int. J. Mol. Sci.201314207042072810.3390/ijms14102070424132155
  20. E. BuzzettiM. PinzaniE.A. TsochatzisThe multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)Metabolism2016651038104810.1016/j.metabol.2015.12.01226823198
  21. L. YangP. LiS. FuE.S. CalayG.S. HotamisligilDefective hepatic autophagy in obesity promotes ER stress and causes insulin resistanceCell Metab.20101146747810.1016/j.cmet.2010.04.00520519119
  22. T. HardyF. OakleyQ.M. AnsteeC.P. DayNonalcoholic Fatty Liver Disease: Pathogenesis and Disease SpectrumAnnu. Rev. Pathol.20161145149610.1146/annurev-pathol-012615-04422426980160
  23. H. MalhiG.J. GoresJ.J. LemastersApoptosis and necrosis in the liver: A tale of two deaths?Hepatology200643S31S4410.1002/hep.2106216447272
  24. L. ChangS.-H. ChiangA.R. SaltielInsulin signaling and the regulation of glucose transportMol. Med.200410657110.2119/2005-00029.Saltiel16307172
  25. V. Martin-DominguezR. Gonzalez-CasasJ. Mendoza-Jimenez-RidruejoL. Garcia-BueyR. Moreno-OteroPathogenesis, diagnosis and treatment of non-alcoholic fatty liver diseaseRev. Esp. Enferm. Dig.201310540942010.4321/S1130-0108201300070000624206551
  26. J.A. ParnellM. RamanK.P. RiouxR.A. ReimerThe potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistanceLiver Int.20123270171110.1111/j.1478-3231.2011.02730.x22221818
  27. R.E. LeyP.J. TurnbaughS. KleinJ.I. GordonMicrobial ecology: Human gut microbes associated with obesityNature20064441022102310.1038/4441022a17183309
  28. C.E. GarnerS. SmithB. de Lacy CostelloP. WhiteR. SpencerC.S.J. ProbertN.M. RatcliffeVolatile organic compounds from feces and their potential for diagnosis of gastrointestinal diseaseFASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.2007211675168810.1096/fj.06-6927com17314143
  29. M. RamanI. AhmedP.M. GillevetC.S. ProbertN.M. RatcliffeS. SmithR. GreenwoodM. SikaroodiV. LamP. CrottyFecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver diseaseClin. Gastroenterol. Hepatol.20131186386810.1016/j.cgh.2013.02.01523454028
  30. J.P. AllardE. AghdassiS. MohammedM. RamanG. AvandB.M. ArendtP. JalaliT. KandasamyN. PrayitnoM. ShermanNutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional studyJ. Hepatol.20084830030710.1016/j.jhep.2007.09.00918086506
  31. T. EslamparastS. EghtesadA. HekmatdoostH. PoustchiProbiotics and Nonalcoholic Fatty liver DiseaseMiddle East J. Dig. Dis.2013512913624829682
  32. E. JirilloD. CaccavoT. MagroneE. PiccigalloL. AmatiA. LemboC. KalisM. GumenscheimerThe role of the liver in the response to LPS: Experimental and clinical findingsJ. Endotoxin Res.2002831932710.1177/0968051902008005050112537690
  33. A. Abu-ShanabE.M.M. QuigleyThe role of the gut microbiota in nonalcoholic fatty liver diseaseNat. Rev. Gastroenterol. Hepatol.2010769170110.1038/nrgastro.2010.17221045794
  34. J.P. NolanEndotoxin, reticuloendothelial function, and liver injuryHepatology1981145846510.1002/hep.18400105167030906
  35. H. TilgA.R. MoschenEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesisHepatology2010521836184610.1002/hep.2400121038418
  36. M.J. Saez-LaraC. Robles-SanchezF.J. Ruiz-OjedaJ. Plaza-DiazA. GilEffects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical TrialsInt. J. Mol. Sci.20161792810.3390/ijms1706092827304953
  37. Y. IlanLeaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitisWorld J. Gastroenterol.2012182609261810.3748/wjg.v18.i21.260922690069
  38. J.N. FainS.W. BahouthA.K. MadanTNFalpha release by the nonfat cells of human adipose tissueInt. J. Obes. Relat. Metab. Disord.20042861662210.1038/sj.ijo.080259414770194
  39. M.H. WehmeyerB.-C. ZyriaxB. JagemannE. RothE. WindlerJ. Schulze Zur WieschA.W. LohseJ. KluweNonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary patternMedicine (Baltimore)201695e388710.1097/MD.000000000000388727281105
  40. H. Cortez-PintoL. JesusH. BarrosC. LopesM.C. MouraM.E. CamiloHow different is the dietary pattern in non-alcoholic steatohepatitis patients?Clin. Nutr.20062581682310.1016/j.clnu.2006.01.02716677739
  41. V. VolynetsM.A. KuperS. StrahlI.B. MaierA. SprussS. WagnerbergerA. KonigsrainerS.C. BischoffI. BergheimNutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD)Dig. Dis. Sci.2012571932194110.1007/s10620-012-2112-922427130
  42. K. ToshimitsuB. MatsuuraI. OhkuboT. NiiyaS. FurukawaY. HiasaM. KawamuraK. EbiharaM. OnjiDietary habits and nutrient intake in non-alcoholic steatohepatitisNutrition200723465210.1016/j.nut.2006.09.00417140767
  43. Q. JiaY. XiaQ. ZhangH. WuH. DuL. LiuC. WangH. ShiX. GuoX. LiuDietary patterns are associated with prevalence of fatty liver disease in adultsEur. J. Clin. Nutr.20156991492110.1038/ejcn.2014.29725649235
  44. R. TajimaT. KimuraA. EnomotoK. YanoshitaA. SaitoS. KobayashiK. MasudaK. IidaAssociation between rice, bread, and noodle intake and the prevalence of non-alcoholic fatty liver disease in Japanese middle-aged men and womenClin. Nutr.201610.1016/j.clnu.2016.09.03427773550
  45. Y. ChengK. ZhangY. ChenY. LiY. LiK. FuR. FengAssociations between Dietary Nutrient Intakes and Hepatic Lipid Contents in NAFLD Patients Quantified by (1)H-MRS and Dual-Echo MRINutrients2016852710.3390/nu809052727618908
  46. Y. KobayashiH. TatsumiM. HattoriH. SugiyamaS. WadaM. KuwahataS. TanakaK. KanemasaY. SumidaY. NaitoComparisons of dietary intake in Japanese with non-alcoholic fatty liver disease and type 2 diabetes mellitusJ. Clin. Biochem. Nutr.20165921521910.3164/jcbn.16-727895389
  47. Y. SongJ.E. MansonJ.E. BuringS. LiuA prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: The women’s health studyDiabetes Care2004272108211510.2337/diacare.27.9.210815333470
  48. L. ShiZ.W. LiuY. LiC. GongH. ZhangL.J. SongC.Y. HuangM. LiThe prevalence of nonalcoholic fatty liver disease and its association with lifestyle/dietary habits among university faculty and staff in ChengduBiomed. Environ. Sci.20122538339110.3967/0895-3988.2012.04.00223026517
  49. K.S. CollisonZ. MaqboolS.M. SalehA. InglisN.J. MakhoulR. BakheetM. Al-JohiR. Al-RabiahM.Z. ZaidiF.A. Al-MohannaEffect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver diseaseJ. Lipid Res.2009501521153710.1194/jlr.M800418-JLR20019001666
  50. H.E. Da SilvaB.M. ArendtS.A. NoureldinG. TherapondosM. GuindiJ.P. AllardA cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs. healthy controlsJ. Acad. Nutr. Diet.20141141181119410.1016/j.jand.2014.01.00924631112
  51. L. CordainS.B. EatonA. SebastianN. MannS. LindebergB.A. WatkinsJ.H. O’KeefeJ. Brand-MillerOrigins and evolution of the Western diet: Health implications for the 21st centuryAm. J. Clin. Nutr.20058134135415699220
  52. M.B. SchulzeJ.E. MansonW.C. WillettF.B. HuProcessed meat intake and incidence of Type 2 diabetes in younger and middle-aged womenDiabetologia2003461465147310.1007/s00125-003-1220-714576980
  53. G.S. De CastroP.C. CalderNon-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acidsClin. Nutr.201710.1016/j.clnu.2017.01.00628139281
  54. J. ArayaR. RodrigoL.A. VidelaL. ThielemannM. OrellanaP. PettinelliJ. PoniachikIncrease in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver diseaseClin. Sci. (Lond.)200410663564310.1042/CS2003032614720121
  55. T. KishinoH. OhnishiK. OhtsukaS. MatsushimaT. UrataK. WatanebeY. HondaY. MineM. MatsumotoK. NishikawaLow concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injuryClin. Chem. Lab. Med.20114915916210.1515/CCLM.2011.02021034259
  56. J.-S. ZhengA. XuT. HuangX. YuD. LiLow docosahexaenoic acid content in plasma phospholipids is associated with increased non-alcoholic fatty liver disease in ChinaLipids20124754955610.1007/s11745-012-3671-422527845
  57. G. MarchesiniS. PettaR. Dalle GraveDiet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practiceHepatology2016632032204310.1002/hep.2839226663351
  58. M. CaveI. DeaciucC. MendezZ. SongS. Joshi-BarveS. BarveC. McClainNonalcoholic fatty liver disease: Predisposing factors and the role of nutritionJ. Nutr. Biochem.20071818419510.1016/j.jnutbio.2006.12.00617296492
  59. G. BucklandA. BachL. Serra-MajemObesity and the Mediterranean diet: A systematic review of observational and intervention studiesObes. Rev.2008958259310.1111/j.1467-789X.2008.00503.x18547378
  60. F. SofiF. CesariR. AbbateG.F. GensiniA. CasiniAdherence to Mediterranean diet and health status: Meta-analysisBMJ2008337a134410.1136/bmj.a134418786971
  61. M.D. KontogianniN. TileliA. MargaritiM. GeorgoulisM. DeutschD. TiniakosE. FragopoulouR. ZafiropoulouY. ManiosG. PapatheodoridisAdherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver diseaseClin. Nutr.20143367868310.1016/j.clnu.2013.08.01424064253
  62. L. AbenavoliN. MilicV. PetaF. AlfieriA. De LorenzoS. BellentaniAlimentary regimen in non-alcoholic fatty liver disease: Mediterranean dietWorld J. Gastroenterol.201420168311684010.3748/wjg.v20.i45.1683125492997
  63. L. BozzettoA. PrinsterG. AnnuzziL. CostagliolaA. MangioneA. VitelliR. MazzarellaM. LongobardoM. ManciniC. VigoritoLiver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patientsDiabetes Care2012351429143510.2337/dc12-003322723581
  64. M.C. RyanC. ItsiopoulosT. ThodisG. WardN. TrostS. HofferberthK. O’DeaP.V. DesmondN.A. JohnsonA.M. WilsonThe Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver diseaseJ. Hepatol.20135913814310.1016/j.jhep.2013.02.01223485520
  65. S. Zelber-SagiF. SalomoneL. MlynarskyThe Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanismsLiver Int.20173793694910.1111/liv.1343528371239
  66. J. Lopez-MirandaF. Perez-JimenezE. RosR. De CaterinaL. BadimonM.I. CovasE. EscrichJ.M. OrdovasF. SoriguerR. AbiaOlive oil and health: Summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008Nutr. Metab. Cardiovasc. Dis.20102028429410.1016/j.numecd.2009.12.00720303720
  67. F. SalomoneJ. GodosS. Zelber-SagiNatural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectivesLiver Int.20163652010.1111/liv.1297526436447
  68. A. FedericoM. DallioJ. GodosC. LoguercioF. SalomoneTargeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: Translational and clinical evidenceTransl. Res.201616711612410.1016/j.trsl.2015.08.00226318867
  69. F.M. SacksL.P. SvetkeyW.M. VollmerL.J. AppelG.A. BrayD. HarshaE. ObarzanekP.R. ConlinE.R. Miller 3rdD.G. Simons-MortonEffects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research GroupN. Engl. J. Med.200134431010.1056/NEJM20010104344010111136953
  70. A.M. ZivkovicJ.B. GermanA.J. SanyalComparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver diseaseAm. J. Clin. Nutr.20078628530017684197
  71. A.D. LieseM. NicholsX. SunR.B.J. D’AgostinoS.M. HaffnerAdherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: The insulin resistance atherosclerosis studyDiabetes Care2009321434143610.2337/dc09-022819487638
  72. T.T. FungS.E. ChiuveM.L. McCulloughK.M. RexrodeG. LogroscinoF.B. HuAdherence to a DASH-style diet and risk of coronary heart disease and stroke in womenArch. Intern. Med.200816871372010.1001/archinte.168.7.71318413553
  73. A. HekmatdoostA. ShamsipourM. MeibodiN. GheibizadehT. EslamparastH. PoustchiAdherence to the Dietary Approaches to Stop Hypertension (DASH) and risk of Nonalcoholic Fatty Liver DiseaseInt. J. Food Sci. Nutr.2016671024102910.1080/09637486.2016.121010127436528
  74. M. Razavi ZadeM.H. TelkabadiF. BahmaniB. SalehiS. FarshbafZ. AsemiThe effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: A randomized clinical trialLiver Int.20163656357110.1111/liv.1299026503843
  75. J.H. JohnS. ZieblandP. YudkinL.S. RoeH.A.W. NeilEffects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: A randomised controlled trialLancet20023591969197410.1016/S0140-6736(02)98858-612076551
  76. A.B. RossJ.-P. GodinK. MinehiraJ.P. KirwanIncreasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver diseaseInt. J. Endocrinol.2013201358587610.1155/2013/58587623762052
  77. V. GuptaX.-J. MahM.C. GarciaC. AntonypillaiD. van der PoortenOily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver diseaseWorld J. Gastroenterol.201521106211063510.3748/wjg.v21.i37.1062126457022
  78. J.M. RippeT.J. AngelopoulosSugars, obesity, and cardiovascular disease: Results from recent randomized control trialsEur. J. Nutr.201655455310.1007/s00394-016-1257-227418186
  79. M.I. PikilidouA.N. LasaridisP.A. SarafidisC.D. BefaniG.G. KoliakosI.M. TziolasK.A. KazakosJ.G. YovosP.M. NilssonInsulin sensitivity increase after calcium supplementation and change in intraplatelet calcium and sodium-hydrogen exchange in hypertensive patients with Type 2 diabetesDiabet. Med.20092621121910.1111/j.1464-5491.2009.02673.x19317814
  80. D. Almoznino-SarafianS. BermanA. MorM. ShteinshnaiderO. GorelikI. TzurI. AlonD. ModaiN. CohenMagnesium and C-reactive protein in heart failure: An anti-inflammatory effect of magnesium administration?Eur. J. Nutr.20074623023710.1007/s00394-007-0655-x17479208
  81. H.F. LopesK.L. MartinK. NasharJ.D. MorrowT.L. GoodfriendB.M. EganDASH diet lowers blood pressure and lipid-induced oxidative stress in obesityHypertension20034142243010.1161/01.HYP.0000053450.19998.1112623938
  82. M. RoberfroidG.R. GibsonL. HoylesA.L. McCartneyR. RastallI. RowlandD. WolversB. WatzlH. SzajewskaB. StahlPrebiotic effects: Metabolic and health benefitsBr. J. Nutr.2010104Suppl. 2S1S6310.1017/S000711451000336320920376
  83. M. BeylotEffects of inulin-type fructans on lipid metabolism in man and in animal modelsBr. J. Nutr.200593Suppl. 1S163S16810.1079/BJN2004133915877890
  84. J.A. ParnellR.A. ReimerWeight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adultsAm. J. Clin. Nutr.2009891751175910.3945/ajcn.2009.2746519386741
  85. C.A. DaubioulY. HorsmansP. LambertE. DanseN.M. DelzenneEffects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: Results of a pilot studyEur. J. Clin. Nutr.20055972372610.1038/sj.ejcn.160212715770222
  86. P.C. CalderVery long chain omega-3 (n-3) fatty acids and human healthEur. J. Lipid Sci. Technol.20141161280130010.1002/ejlt.201400025
  87. E. ScorlettiC.D. ByrneOmega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver diseaseAnnu. Rev. Nutr.20133323124810.1146/annurev-nutr-071812-16123023862644
  88. M. CapanniF. CalellaM.R. BiaginiS. GeniseL. RaimondiG. BedogniG. Svegliati-BaroniF. SofiS. MilaniR. AbbateProlonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot studyAliment. Pharmacol. Ther.2006231143115110.1111/j.1365-2036.2006.02885.x16611275
  89. L. SpadaroO. MaglioccoD. SpampinatoS. PiroC. OliveriC. AlagonaG. PapaA.M. RabuazzoF. PurrelloEffects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver diseaseDig. Liver Dis.20084019419910.1016/j.dld.2007.10.00318054848
  90. F.-S. ZhuS. LiuX.-M. ChenZ.-G. HuangD.-W. ZhangEffects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemiaWorld J. Gastroenterol.2008146395640010.3748/wjg.14.639519009658
  91. A.J. SanyalM.F. AbdelmalekA. SuzukiO.W. CummingsM. ChojkierNo significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trialGastroenterology2014147377.el384.e110.1053/j.gastro.2014.04.04624818764
  92. M.A. NogueiraC.P. OliveiraV.A. Ferreira AlvesJ.T. StefanoL.S.D.R. RodriguesR.S. TorrinhasB. CogliatiH. BarbeiroF.J. CarrilhoD.L. WaitzbergOmega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trialClin. Nutr.20163557858610.1016/j.clnu.2015.05.00126047766
  93. Z. YariM. RahimlouT. EslamparastN. Ebrahimi-DaryaniH. PoustchiA. HekmatdoostFlaxseed supplementation in non-alcoholic fatty liver disease: A pilot randomized, open labeled, controlled studyInt. J. Food Sci. Nutr.20166746146910.3109/09637486.2016.116101126983396
  94. J.D. BrowningJ.A. BakerT. RogersJ. DavisS. SatapatiS.C. BurgessShort-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restrictionAm. J. Clin. Nutr.2011931048105210.3945/ajcn.110.00767421367948
  95. E. KirkD.N. ReedsB.N. FinckS.M. MayurranjanB.W. PattersonS. KleinDietary fat and carbohydrates differentially alter insulin sensitivity during caloric restrictionGastroenterology20091361552156010.1053/j.gastro.2009.01.04819208352
  96. S. HaufeS. EngeliP. KastJ. BohnkeW. UtzV. HaasM. HermsdorfA. MahlerS. WiesnerA.L. BirkenfeldRandomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjectsHepatology2011531504151410.1002/hep.2424221400557
  97. D. TendlerS. LinW.S.J. YancyJ. MavropoulosP. SylvestreD.C. RockeyE.C. WestmanThe effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: A pilot studyDig. Dis. Sci.20075258959310.1007/s10620-006-9433-517219068
  98. D.A. De LuisR. AllerO. IzaolaM. Gonzalez SagradoR. CondeEffect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patientsNutr. Hosp.20102573073521336428
  99. C.N. KatsagoniM. GeorgoulisG.V. PapatheodoridisD.B. PanagiotakosM.D. KontogianniEffects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysisMetabolism20176811913210.1016/j.metabol.2016.12.00628183444
  100. A. VelayudhamA. DolganiucM. EllisJ. PetrasekK. KodysP. MandrekarG. SzaboVSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in miceHepatology20094998999710.1002/hep.2271119115316
  101. V.W.-S. WongG.L.-H. WonA.M.-L. ChimW.C.-W. ChuD.K.-W. YeungK.C.-T. LiH.L.-Y. ChanTreatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept studyAnn. Hepatol.20131225626223396737
  102. C.K. ArgoJ.T. PatrieC. LacknerT.D. HenryE.E. de LangeA.L. WeltmanN.L. ShahA.M. Al-OsaimiP. PramoonjagoS. JayakumarEffects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trialJ. Hepatol.20156219019710.1016/j.jhep.2014.08.03625195547
  103. S. NabaviM. RafrafM.H. SomiA. Homayouni-RadM. Asghari-JafarabadiEffects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver diseaseJ. Dairy Sci.2014977386739310.3168/jds.2014-850025306266
  104. F.M. TrovatoD. CatalanoG.F. MartinesP. PaceG.M. TrovatoMediterranean diet and non-alcoholic fatty liver disease: The need of extended and comprehensive interventionsClin. Nutr.201534868810.1016/j.clnu.2014.01.01824529325
  105. L. AbenavoliM. GrecoI. NazionaleV. PetaN. MilicF. AccattatoD. FotiE. GullettaF. LuzzaEffects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver diseaseExpert Rev. Gastroenterol. Hepatol.2015951952710.1586/17474124.2015.100431225617046
  106. A. HatzitoliosC. SavopoulosG. LazarakiI. SidiropoulosP. HaritantiA. LefkopoulosG. KaragiannopoulouV. TzioufaK. DimitriosEfficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemiaIndian J. Gastroenterol.20042313113415333967
  107. N. TanakaK. SanoA. HoriuchiE. TanakaK. KiyosawaT. AoyamaHighly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitisJ. Clin. Gastroenterol.20084241341810.1097/MCG.0b013e31815591aa18277895
  108. G.L. VegaM. ChandaliaL.S. SzczepaniakS.M. GrundyEffects of N-3 fatty acids on hepatic triglyceride content in humansJ. Investig. Med.20085678078510.2310/JIM.0b013e318177024d18525453
  109. E. ScorlettiL. BhatiaK.G. McCormickG.F. CloughK. NashP.C. CalderC.D. ByrneDesign and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]Contemp. Clin. Trials20143730131110.1016/j.cct.2014.02.00224556343
  110. S. DasarathyJ. DasarathyA. KhiyamiL. YerianC. HawkinsR. SargentA.J. McCulloughDouble-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitisJ. Clin. Gastroenterol.20154913714410.1097/MCG.000000000000009924583757
  111. Y.-H. LiL.-H. YangK.-H. ShaT.-G. LiuL.-G. ZhangX.-X. LiuEfficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitisWorld J. Gastroenterol.2015217008701310.3748/wjg.v21.i22.700826078579
  112. K.F. PetersenS. DufourD. BefroyM. LehrkeR.E. HendlerG.I. ShulmanReversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetesDiabetes20055460360810.2337/diabetes.54.3.60315734833
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5579594/fullTextXML. The license for the article is Creative Commons Attribution. The main subject has been identified as obesity.